Date of Abstract presentation9th December 2023IndicationsChronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)Abstract Number330Abstract typeOral
TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after progression on a BTK inhibitor (BTKi) and BCL-2 inhibitor (BCL2i). The study included a broad population of patients with relapsed or refractory CLL or SLL with high unmet need who had received at least two prior lines of therapy, including a BTKi (n=118), to be treated with BREYANZI. According to the findings presented at the AS...
